MetaVia is a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies.
MetaVia has raised $9.3M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2026.
MetaVia's investors include Silicon Valley Bank.
MetaVia is headquartered in Boston, United States.
MetaVia is a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies.
MetaVia is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MetaVia — Funding & Investors." VCBacked, January 15, 2026, https://www.vcbacked.co/company/metavia. Accessed August 14, 2026.
VCBacked. (2026). MetaVia — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/metavia
{{cite web |title=MetaVia — Funding & Investors |url=https://www.vcbacked.co/company/metavia |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated